|
[1]
|
Collis S J, DeWeese TL. Enhanced radiation response through directed molecular targeting approaches. Cancer Metastasis Rev, 2004, 23(3-4):277-292. |
|
[2]
|
Baker SJ, Markowitz S, Fearon ER, et al. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science, 1990, 249(4971):912-915. |
|
[3]
|
Hanpt S, Haupt Y. Importance of p53 for cancer onset and therapy. Anticancer Drugs, 2006, 17(7):725-732. |
|
[4]
|
Mimeault M, Batra SK. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis, 2006, 27(1):1-22. |
|
[5]
|
Guha A, Mukherjee J. Advances in the biology of astrocytomas. Curt Opin Neurol, 2004, 17(6):655-662. |
|
[6]
|
|
|
[7]
|
Moon C, Oh Y, Roth JA. Current status of gene therapy for lung cancer and head and neck cancer. Clin Cancer Res, 2003, 9(14):5055-5067. |
|
[8]
|
Lavin MF, Khanna KK. ATM:the protein encoded by the gene mutated in the radiosen-sitive syndrome ataxia-telangiectasia. Int J Radiat Biol, 1999, 75(10):1201-1214. |
|
[9]
|
Fan Z, Chakravarty P, Alfieri A, et al. Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation. Cancer Gene Ther, 2000, 7(10):1307-1314. |
|
[10]
|
Guha C, Guha U, Tribius S, et al. Antisense ATM gene therapy:a strategy to increase the radiosensitivity of human tumors. Gene Ther, 2000, 7(10):852-858. |
|
[11]
|
Normanno N, Maiello MR, De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs):simple drugs with a complex mechanism of action?. J Cell Physiol, 2003, 194(1):13-19. |
|
[12]
|
Harari PM, Huang SM. Epidermal growth factor receptor modulation of radiation response:preclinical and clinical development. Semin Radiat Oncol, 2002, 12(3 Suppl 2):21-26. |
|
[13]
|
Harari PM, Huang SM. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol, 2001,11(4):281-289. |
|
[14]
|
Taira N, Doihara H, Oota T, et al. Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro. Acta Med Okayama, 2006, 60(1):25-34. |
|
[15]
|
Dobelbower MC, Russo SM, Raisch KP, et al. Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer:a phase I study. Anticancer Drugs, 2006, 17(1):95-102. |
|
[16]
|
Vlachaki MT, Chhikara M, Aguilar L, et al. Enhanced therapeutic effect of multiple injections of HSV-TK +GCV gene therapy in combination with ionizing radiation in a mouse nmannary tumor model. Int J Radiat Oncol Biol Phys, 2001, 51(4):1008-1017. |
|
[17]
|
Chhikara M, Huang H, Vlachaki MT, et al. Enhanced therapeutic effect of HSV-tk +GCV genetherapy and ionizing radiation for prostate cancer. Mol Ther, 2001:3(4):536-542. |
|
[18]
|
Stackhouse MA, Pederson LC, Grizzle WE, et al. Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models. Gene Ther, 2000, 7(12):1019-1026. |
|
[19]
|
Freytag SO, Strieker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed interme-diate-to high-risk prostate cancer. Cancer Res, 2003, 63(21):7497-7506. |
|
[20]
|
张燕,涂文勇.非小细胞肺癌p16基因表达与放疗敏感性的关系.临床肿瘤学杂志,2005,10(6):637-640.
|
|
[21]
|
伍海军,申良方,肖华平,等.增殖细胞核抗原和p16蛋白表达与鼻咽癌放射敏感性相关性研究.中国医师杂志,2007,9(5):619-621.
|
|
[22]
|
|
|
[23]
|
Han JA, Kim JI, Ongusaha PP, et al. P53-mediated induction of Gox-2 counteracts p53-or genotoxic stress-induced apoptosis. EMBO J, 2002, 21(21):5635-5644. |
点击查看大图
下载: